BACKGROUND: Disseminated leishmaniasis (DL) is a severe and emerging form of American tegumentary leishmaniasis, associated primarily with infection by Leishmania brasiliensis. DL is defined by the presence of ≥10 mixed-type lesions such as inflammatory papules and ulcers, located in ≥2 body parts. Most patients have hundreds of lesions all over the body, and mucosal involvement is detected in up to 44% of cases. DL is a difficult to cure disease and pentavalent antimony (Sb(v)) is used as standard treatment, its highest dosage being 20 mg/kg/day, for 30 days. However, less than 25% of DL cases will be cured after standard therapy, and the majority of cases will require more than one course of Sb(v) for a cure. In this context, new therapies are needed that offer a higher cure rate and a better safety profile, with convenience in drug administration. METHODS: We have evaluated liposomal amphotericin B in 20 patients with DL in an open clinical trial. The total dose ranged from 17 to 37 mg/kg, used in 7 to 14 days of treatment. RESULTS: Cure rate at 3 months after therapy was 70%. One relapse was documented 4 months after treatment, producing a final cure rate of 65%. Although liposomal amphotericin B was considered well tolerated, mild adverse events were documented in 75% of the patients. CONCLUSIONS: Liposomal amphotericin B is an effective therapy for DL, with a higher final cure rate of 75% observed when used in a total dose above 30 mg/kg. CLINICAL TRIALS REGISTRATION: NCT02025491.
BACKGROUND:Disseminated leishmaniasis (DL) is a severe and emerging form of American tegumentary leishmaniasis, associated primarily with infection by Leishmania brasiliensis. DL is defined by the presence of ≥10 mixed-type lesions such as inflammatory papules and ulcers, located in ≥2 body parts. Most patients have hundreds of lesions all over the body, and mucosal involvement is detected in up to 44% of cases. DL is a difficult to cure disease and pentavalent antimony (Sb(v)) is used as standard treatment, its highest dosage being 20 mg/kg/day, for 30 days. However, less than 25% of DL cases will be cured after standard therapy, and the majority of cases will require more than one course of Sb(v) for a cure. In this context, new therapies are needed that offer a higher cure rate and a better safety profile, with convenience in drug administration. METHODS: We have evaluated liposomal amphotericin B in 20 patients with DL in an open clinical trial. The total dose ranged from 17 to 37 mg/kg, used in 7 to 14 days of treatment. RESULTS: Cure rate at 3 months after therapy was 70%. One relapse was documented 4 months after treatment, producing a final cure rate of 65%. Although liposomal amphotericin B was considered well tolerated, mild adverse events were documented in 75% of the patients. CONCLUSIONS: Liposomal amphotericin B is an effective therapy for DL, with a higher final cure rate of 75% observed when used in a total dose above 30 mg/kg. CLINICAL TRIALS REGISTRATION: NCT02025491.
Authors: Ana Carolina Santana Vieira; Mariana da Silva Santos; Anderson Brandão Leite; Amanda Evelyn da Silva; Luiz Henrique Agra Cavalcante-Silva; Gabrielle de Souza Augusto Pereira; Sany Delany Gomes Marques; Barbara Viviana de Oliveira Santos; Alysson Wagner Fernandes Duarte; Aline Cavalcante de Queiroz; Kristerson Reinaldo de Luna-Freire; Magna Suzana Alexandre-Moreira Journal: Parasitol Res Date: 2022-01-06 Impact factor: 2.289
Authors: Carvel Suprien; Paulo N Rocha; Marina Teixeira; Lucas P Carvalho; Luiz H Guimarães; Toby Bonvoisin; Paulo R L Machado; Edgar M Carvalho Journal: Am J Trop Med Hyg Date: 2020-04 Impact factor: 2.345
Authors: Lilian S Medina; Bruno Araújo Souza; Adriano Queiroz; Luiz Henrique Guimarães; Paulo Roberto Lima Machado; Edgar M Carvalho; Mary Edythe Wilson; Albert Schriefer Journal: PLoS One Date: 2016-09-20 Impact factor: 3.240
Authors: Camila F Amorim; Luiza Galina; Natália B Carvalho; Nathalia D M Sperotto; Kenia Pissinate; Pablo Machado; Maria M Campos; Luiz A Basso; Valnês S Rodrigues-Junior; Edgar M Carvalho; Diógenes Santiago Santos Journal: PLoS One Date: 2017-12-27 Impact factor: 3.240